{"id":725705,"date":"2023-01-25T08:33:38","date_gmt":"2023-01-25T13:33:38","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-investor-conferences-6\/"},"modified":"2023-01-25T08:33:38","modified_gmt":"2023-01-25T13:33:38","slug":"zymeworks-announces-participation-in-upcoming-investor-conferences-6","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-investor-conferences-6\/","title":{"rendered":"Zymeworks Announces Participation in Upcoming Investor Conferences"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Zymeworks Announces Participation in Upcoming Investor Conferences<\/b><\/p>\n<p>VANCOUVER, British Columbia&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nZymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nGuggenheim Oncology Conference 2023. Zymeworks\u2019 management will participate in one-on-one meetings on February 8<sup>th<\/sup> \u2013 9<sup>th<\/sup> and a fireside chat on February 9<sup>th<\/sup> at 2:10 pm Eastern Time (ET) in New York, NY.\n<\/li>\n<li>\nSVB Securities Global Biopharma Conference. Zymeworks\u2019 management will participate virtually in one-on-one meetings on February 14<sup>th<\/sup> \u2013 15<sup>th<\/sup> and present on February 14<sup>th<\/sup> at 10:40 am ET.\n<\/li>\n<\/ul>\n<p>\nAll presentations and webcasts will be available on Zymeworks\u2019 website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fir.zymeworks.com%2Fevents-and-presentations&amp;esheet=53290656&amp;newsitemid=20230125005240&amp;lan=en-US&amp;anchor=http%3A%2F%2Fir.zymeworks.com%2Fevents-and-presentations&amp;index=1&amp;md5=ced890cb2822615a04babff8b74f174e\">http:\/\/ir.zymeworks.com\/events-and-presentations<\/a>.\n<\/p>\n<p><b>About Zymeworks Inc.<\/b><\/p>\n<p>\nZymeworks Inc. (Nasdaq: ZYME) is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks&#8217; mission is to make a meaningful difference for people impacted by difficult-to-treat cancers and other serious diseases. Zymeworks&#8217; complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using Zymeworks&#8217; proprietary Azymetric\u2122 technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each of BeiGene and Jazz with exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in global Phase 1, Phase 2, and pivotal clinical trials as a treatment for patients with HER2-expressing cancers. Zymeworks&#8217; next clinical candidate, zanidatamab zovodotin (ZW49), is a HER2-targeted bispecific antibody-drug conjugate (ADC) developed using Zymeworks&#8217; proprietary Azymetric\u2122 and ZymeLink\u2122 Auristatin technologies. Zanidatamab zovodotin is currently being evaluated in a Phase 1 clinical trial for patients with a variety of HER2-expressing, HER2-amplified or HER2-mutant cancers. Zymeworks is also advancing a deep pipeline of product candidates based on its experience and capabilities in both ADC and multispecific antibodies (MSAT). In addition to Zymeworks&#8217; wholly-owned pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3742228-1%26h%3D3670077902%26u%3Dhttps%253A%252F%252Fwww.zymeworks.com%252F%26a%3Dwww.zymeworks.com&amp;esheet=53290656&amp;newsitemid=20230125005240&amp;lan=en-US&amp;anchor=www.zymeworks.com&amp;index=2&amp;md5=2fdd6a5ec4563c8be052364ab5d30af0\">www.zymeworks.com<\/a> and follow <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3742228-1%26h%3D2230935422%26u%3Dhttps%253A%252F%252Ftwitter.com%252FZymeworksInc%26a%3D%2540ZymeworksInc&amp;esheet=53290656&amp;newsitemid=20230125005240&amp;lan=en-US&amp;anchor=%40ZymeworksInc&amp;index=3&amp;md5=c2f75a52ab96b455708484085350fe0d\">@ZymeworksInc<\/a> on Twitter.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230125005240r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20230125005240\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20230125005240\/en\/<\/a><\/span><\/p>\n<p>\nInvestor Inquiries:<br \/>\n<br \/>Jack Spinks<br \/>\n<br \/>Associate Director, Investor Relations<br \/>\n<br \/>(604) 678-1388<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:ir@zymeworks.com\">ir@zymeworks.com<br \/>\n<\/a><\/p>\n<p>Media Inquiries:<br \/>\n<br \/>Diana Papove<br \/>\n<br \/>Senior Manager, Corporate Communications<br \/>\n<br \/>(604) 678-1388<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:media@zymeworks.com\">media@zymeworks.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Canada New York<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Oncology Health Clinical Trials General Health Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230125005240\/en\/183056\/3\/Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Zymeworks Announces Participation in Upcoming Investor Conferences VANCOUVER, British Columbia&#8211;(BUSINESS WIRE)&#8211; Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: Guggenheim Oncology Conference 2023. Zymeworks\u2019 management will participate in one-on-one meetings on February 8th \u2013 9th and a fireside chat on February 9th at 2:10 pm Eastern Time (ET) in New York, NY. SVB Securities Global Biopharma Conference. Zymeworks\u2019 management will participate virtually in one-on-one meetings on February 14th \u2013 15th and present on February 14th at 10:40 am ET. All presentations and webcasts will be available on Zymeworks\u2019 website at http:\/\/ir.zymeworks.com\/events-and-presentations. About Zymeworks Inc. Zymeworks Inc. (Nasdaq: ZYME) is a global biotechnology company committed &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-investor-conferences-6\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Zymeworks Announces Participation in Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-725705","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Zymeworks Announces Participation in Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-investor-conferences-6\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zymeworks Announces Participation in Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Zymeworks Announces Participation in Upcoming Investor Conferences VANCOUVER, British Columbia&#8211;(BUSINESS WIRE)&#8211; Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: Guggenheim Oncology Conference 2023. Zymeworks\u2019 management will participate in one-on-one meetings on February 8th \u2013 9th and a fireside chat on February 9th at 2:10 pm Eastern Time (ET) in New York, NY. SVB Securities Global Biopharma Conference. Zymeworks\u2019 management will participate virtually in one-on-one meetings on February 14th \u2013 15th and present on February 14th at 10:40 am ET. All presentations and webcasts will be available on Zymeworks\u2019 website at http:\/\/ir.zymeworks.com\/events-and-presentations. About Zymeworks Inc. Zymeworks Inc. (Nasdaq: ZYME) is a global biotechnology company committed &hellip; Continue reading &quot;Zymeworks Announces Participation in Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-investor-conferences-6\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-25T13:33:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230125005240r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-participation-in-upcoming-investor-conferences-6\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-participation-in-upcoming-investor-conferences-6\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Zymeworks Announces Participation in Upcoming Investor Conferences\",\"datePublished\":\"2023-01-25T13:33:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-participation-in-upcoming-investor-conferences-6\\\/\"},\"wordCount\":413,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-participation-in-upcoming-investor-conferences-6\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230125005240r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-participation-in-upcoming-investor-conferences-6\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-participation-in-upcoming-investor-conferences-6\\\/\",\"name\":\"Zymeworks Announces Participation in Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-participation-in-upcoming-investor-conferences-6\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-participation-in-upcoming-investor-conferences-6\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230125005240r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2023-01-25T13:33:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-participation-in-upcoming-investor-conferences-6\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-participation-in-upcoming-investor-conferences-6\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-participation-in-upcoming-investor-conferences-6\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230125005240r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230125005240r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-participation-in-upcoming-investor-conferences-6\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zymeworks Announces Participation in Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Zymeworks Announces Participation in Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-investor-conferences-6\/","og_locale":"en_US","og_type":"article","og_title":"Zymeworks Announces Participation in Upcoming Investor Conferences - Market Newsdesk","og_description":"Zymeworks Announces Participation in Upcoming Investor Conferences VANCOUVER, British Columbia&#8211;(BUSINESS WIRE)&#8211; Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: Guggenheim Oncology Conference 2023. Zymeworks\u2019 management will participate in one-on-one meetings on February 8th \u2013 9th and a fireside chat on February 9th at 2:10 pm Eastern Time (ET) in New York, NY. SVB Securities Global Biopharma Conference. Zymeworks\u2019 management will participate virtually in one-on-one meetings on February 14th \u2013 15th and present on February 14th at 10:40 am ET. All presentations and webcasts will be available on Zymeworks\u2019 website at http:\/\/ir.zymeworks.com\/events-and-presentations. About Zymeworks Inc. Zymeworks Inc. (Nasdaq: ZYME) is a global biotechnology company committed &hellip; Continue reading \"Zymeworks Announces Participation in Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-investor-conferences-6\/","og_site_name":"Market Newsdesk","article_published_time":"2023-01-25T13:33:38+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230125005240r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-investor-conferences-6\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-investor-conferences-6\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Zymeworks Announces Participation in Upcoming Investor Conferences","datePublished":"2023-01-25T13:33:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-investor-conferences-6\/"},"wordCount":413,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-investor-conferences-6\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230125005240r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-investor-conferences-6\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-investor-conferences-6\/","name":"Zymeworks Announces Participation in Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-investor-conferences-6\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-investor-conferences-6\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230125005240r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2023-01-25T13:33:38+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-investor-conferences-6\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-investor-conferences-6\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-investor-conferences-6\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230125005240r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230125005240r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-investor-conferences-6\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Zymeworks Announces Participation in Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/725705","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=725705"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/725705\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=725705"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=725705"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=725705"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}